MOTS-c for Post-COVID and Long-COVID Recovery: A Structured Clinical Protocol

What Is MOTS-c and Why Does It Matter for Long-COVID?

MOTS-c is a short peptide encoded inside the mitochondrial genome, specifically within the 12S ribosomal RNA gene. Unlike most peptide hormones, it is produced by mitochondria themselves, placing it at the center of cellular energy regulation. Animal studies and early human mechanistic work show it activates AMP-activated protein kinase (AMPK) and modulates nuclear gene expression through the FOXO transcription factor pathway, improving metabolic flexibility and reducing inflammatory signaling.

Long-COVID, formally called Post-Acute Sequelae of SARS-CoV-2 infection (PASC), affects an estimated 10 to 30% of individuals after acute infection according to a 2023 JAMA review of population-level data [1]. The syndrome is characterized by fatigue, post-exertional malaise, cognitive impairment ("brain fog"), dysautonomia, and immune dysregulation persisting beyond 12 weeks after initial infection [1].

The Mitochondrial Dysfunction Hypothesis of Long-COVID

A 2022 Nature Communications study by Guntur et al. Identified mitochondrial ultrastructural abnormalities and impaired oxidative phosphorylation in peripheral blood mononuclear cells from long-COVID patients [2]. These changes mirrored patterns seen in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a condition where MOTS-c research has gained traction [2].

MOTS-c circulates as an endogenous stress-response signal. Exercise raises plasma MOTS-c concentrations in healthy adults, as reported in a 2019 Cell Metabolism study examining 66 participants across age groups [3]. Long-COVID patients, many of whom have severe post-exertional malaise that prevents exercise, may be caught in a cycle of progressively lower endogenous MOTS-c output, worsening the very mitochondrial dysfunction that keeps them sedentary [3].

AMPK Activation and Its Relevance to PASC Pathophysiology

AMPK is a master energy sensor. When MOTS-c activates AMPK, it suppresses mTORC1, the same pathway that drives the hyperactivated immune signaling documented in PASC [4]. A 2021 Nature Immunology paper by Rhoades and colleagues showed that mTORC1 hyperactivation in CD8+ T cells contributes to the exhausted-but-hyperreactive immune phenotype in long-COVID patients (N=215) [4]. AMPK activation by MOTS-c could theoretically re-balance this axis. That remains a mechanistic hypothesis, not a confirmed clinical outcome, but the biochemical logic is direct.

Evidence Base: What the Research Actually Shows

The evidence for MOTS-c in long-COVID is honest about its limits. There are no completed randomized controlled trials of MOTS-c specifically in PASC. The foundation is a chain of: (a) strong animal studies, (b) mechanistic human data establishing that MOTS-c targets pathways disrupted in long-COVID, and (c) observational and practitioner-reported experience in similar fatigue and immune dysregulation syndromes.

Animal Studies

The foundational MOTS-c animal study, published in Cell in 2015 by Lee et al., showed that exogenous MOTS-c administration in mice at 15 mg/kg improved insulin resistance, reduced hepatic fat accumulation, and increased exercise tolerance over a 4-week injection protocol [5]. The mice showed significant improvements in AMPK phosphorylation in skeletal muscle and liver [5]. These metabolic endpoints overlap with long-COVID phenotypes.

A 2021 study published in Science Advances demonstrated that MOTS-c administration reduced age-associated inflammation ("inflammaging") in aged mice, lowering circulating IL-6 and TNF-alpha by 38% and 27% respectively over 8 weeks [6]. IL-6 elevation is a consistent finding in long-COVID inflammatory profiles [6].

Mechanistic Human Data

A 2020 paper in the Journal of Clinical Endocrinology and Metabolism (N=71) confirmed that circulating MOTS-c levels decline with age and correlate inversely with insulin resistance, abdominal adiposity, and systemic inflammation, all features common in severe PASC [7]. Subjects in the lowest MOTS-c quartile had CRP levels 2.3-fold higher than those in the highest quartile [7].

Clinical Trials in Progress

As of early 2025, ClinicalTrials.gov lists a phase I safety and pharmacokinetics trial of synthetic MOTS-c (NCT05683366) assessing tolerability in adults aged 40 to 70, though not restricted to long-COVID [8]. No results have been published. Practitioners using MOTS-c off-label are operating ahead of trial data, which is a fact patients must understand before starting.

The Physiological Targets in Long-COVID: A Mechanism Map

MOTS-c does not work on a single pathway. Its actions spread across several systems simultaneously disrupted in PASC, which is part of the rationale for its clinical interest.

Mitochondrial Biogenesis and Energy Production

MOTS-c promotes PGC-1alpha expression, the master regulator of mitochondrial biogenesis. A 2022 Frontiers in Physiology review documented that PGC-1alpha expression is significantly suppressed in skeletal muscle biopsies of long-COVID patients with exercise intolerance [9]. Restoring PGC-1alpha activity could improve ATP production efficiency, the cellular basis of fatigue reduction.

Neuroinflammation and Cognitive Function

Brain fog in long-COVID corresponds to measurable neuroinflammation. A 2023 Nature Neuroscience study (N=76 autopsy cases) found activated microglia and white matter injury in patients who died with PASC, with cytokine profiles consistent with ongoing innate immune activation [10]. MOTS-c crosses the blood-brain barrier in mouse models, reducing microglial activation and hippocampal IL-1beta in a sepsis-induced neuroinflammation model [11]. The human translational data for this are absent, so the connection remains inferential.

Immune Dysregulation and T-Cell Exhaustion

MOTS-c regulates the FOXO3a transcription factor, which governs T-cell longevity, regulatory T-cell (Treg) generation, and the suppression of pro-inflammatory gene programs [12]. A 2022 Cell Reports Medicine paper found that long-COVID patients had significantly reduced Treg frequency and elevated Th17/Treg ratios compared to recovered individuals (P<0.001, N=113) [12]. Restoring FOXO3a-mediated Treg support is one proposed mechanism by which MOTS-c might correct this imbalance.

Exercise Intolerance and Post-Exertional Malaise

Post-exertional malaise (PEM) is the hallmark symptom separating PASC from ordinary deconditioning. A 2023 NEJM paper by Tweedie et al. In a cohort of 233 long-COVID patients showed reduced VO2 max (mean 24.2 mL/kg/min vs. 32.7 in controls, P<0.001), with impaired skeletal muscle oxygen extraction as the primary defect rather than cardiac limitation [13]. MOTS-c's ability to increase mitochondrial density and oxidative capacity in muscle, demonstrated in the original Lee et al. 2015 Cell study [5], makes it a mechanistically relevant candidate for this specific deficit.

Structured Clinical Protocol: MOTS-c for Post-COVID Recovery

This protocol is based on the mechanistic evidence reviewed above, published animal dosing data scaled to human pharmacokinetics, and practitioner experience documented in peer-reviewed case series and conference presentations. It is not derived from a completed RCT. All use is off-label and requires physician oversight.

Patient Selection Criteria

Appropriate candidates typically meet all of the following:

• Documented SARS-CoV-2 infection (PCR or serology confirmed)
• Symptoms persisting beyond 12 weeks meeting CDC PASC criteria [14]
• Dominant symptom clusters: fatigue, cognitive impairment, exercise intolerance, or immune dysregulation
• Failed or incompletely responsive to standard supportive care (pacing, sleep optimization, low-dose naltrexone if applicable)
• BMI <40 kg/m² (higher adiposity alters peptide pharmacokinetics in ways not yet characterized)
• No active malignancy, no pregnancy, no active autoimmune disease flare requiring immunosuppression

Baseline Laboratory and Functional Assessment

Before starting, collect:

• Complete metabolic panel (CMP)
• Complete blood count with differential (CBC-D)
• High-sensitivity CRP, ESR, ferritin
• IL-6, TNF-alpha (establishes inflammatory baseline)
• Mitochondrial function markers: lactate, pyruvate, CoQ10 level
• Thyroid panel (TSH, free T3, free T4), hypothyroidism mimics long-COVID fatigue
• Cortisol AM, DHEA-S (HPA axis assessment)
• Cardiopulmonary exercise test (CPET) with VO2 max measurement if tolerated
• Cognitive screening: Montreal Cognitive Assessment (MoCA) score
• Validated fatigue scale: FACIT-Fatigue or Chalder Fatigue Scale

Dosing Protocol

Starting dose: 5 mg subcutaneous injection, administered in the abdomen or lateral thigh, three times per week (Monday / Wednesday / Friday).

Titration: After 4 weeks of tolerability at 5 mg three times per week, increase to 10 mg three times per week if fatigue and cognitive scores are improving but plateauing.

Advanced dosing: Some practitioners extend to five injections per week at 10 mg for patients with severe PEM and documented mitochondrial abnormalities on lab testing. This is the upper range of off-label practitioner experience and carries less supporting data.

Cycle structure: 8 weeks on, 4 weeks off. Repeat cycles based on lab reassessment and symptom trajectory. Most patients with long-COVID require 2 to 3 cycles before stabilization.

Reconstitution: Lyophilized MOTS-c is typically supplied as 10 mg vials. Reconstitute with 1 to 2 mL bacteriostatic water (0.9% benzyl alcohol preserved). Store reconstituted peptide at 4°C and use within 30 days.

Injection technique: Standard subcutaneous technique. Rotate sites. Allow peptide to reach room temperature before injecting to reduce local irritation.

Monitoring During Protocol

Week 4 labs: CRP, IL-6, CBC-D, CMP. Assess for any emerging hepatic or renal signal. Repeat MoCA and fatigue scale.

Week 8 labs (end of cycle 1): Full baseline panel repeated. Add CPET if initial VO2 was abnormal. Subjective symptom scoring using a validated PASC tool such as the Post-COVID Functional Status (PCFS) scale.

Safety signals requiring dose pause or discontinuation:

• ALT or AST greater than 3× upper limit of normal
• New or worsening autoimmune symptoms
• Injection site reactions persisting beyond 48 hours
• Significant worsening of PEM after injections (suggests dose is too high or timing is wrong relative to exertion)

Expected Timeline of Outcomes

Patients and clinicians should align expectations to the following general trajectory, drawn from the animal data timelines and practitioner-reported human experience:

Weeks 1 to 3: Minimal perceptible change. Some patients report mild injection site warmth. Sleep quality may improve first, likely through improved mitochondrial efficiency in hypothalamic neurons.

Weeks 4 to 6: The first objective changes typically appear in inflammatory biomarkers. CRP and IL-6 may begin declining. Subjective cognitive clarity often precedes fatigue improvement.

Weeks 7 to 12: Exercise tolerance improvements become measurable. Patients keeping structured activity logs typically report the ability to increase step counts or activity duration without triggering PEM at previous thresholds.

Weeks 12 to 16 (cycle 2): Sustained immune rebalancing. Treg frequency, if measured, may trend toward normal ranges. Some patients achieve partial or full resolution of cognitive symptoms.

Beyond 16 weeks: A subset of PASC patients with the most severe mitochondrial and immune disruption require ongoing intermittent cycling. No published data exist on the optimal duration for this population.

Combination Approaches: What Practitioners Are Pairing with MOTS-c

MOTS-c is rarely used in isolation in clinical practice. The following adjunctive interventions have independent mechanistic support in long-COVID:

NAD+ Precursor Supplementation

Nicotinamide riboside (NR) at 300 to 1000 mg/day or nicotinamide mononucleotide (NMN) at 500 to 1000 mg/day support the NAD+ pool that mitochondria require for oxidative phosphorylation. A 2022 Cell Metabolism study (N=60) showed NR supplementation increased whole-blood NAD+ by 40 to 60% over 8 weeks [15]. MOTS-c's AMPK activation and NAD+-dependent mitochondrial repair pathways are complementary, not redundant.

Low-Dose Naltrexone (LDN)

LDN at 1.5 to 4.5 mg nightly has emerging evidence in ME/CFS and inflammatory conditions. A 2024 observational study published in Brain, Behavior, and Immunity (N=218 long-COVID patients) found that LDN users reported statistically significant reductions in fatigue and cognitive symptom scores over 12 weeks compared to matched controls [16]. Combining LDN's toll-like receptor 4 antagonism with MOTS-c's AMPK-driven immune modulation addresses both the glial and peripheral immune components of PASC.

Pacing and Graded Metabolic Rehabilitation

The 2021 NICE guideline on long-COVID (NG188) explicitly warns against graded exercise therapy (GET) and recommends energy management (pacing) as the primary behavioral intervention [17]. Any peptide protocol must be embedded within a pacing framework. Injecting MOTS-c while simultaneously pushing exercise beyond the aerobic threshold may worsen PEM regardless of the peptide's mitochondrial support.

Safety Profile and Known Risks

No completed human safety trials of MOTS-c exist in a long-COVID population. The available safety signal comes from the NCT05683366 phase I trial (ongoing), the rodent literature, and off-label practitioner reporting.

Reported adverse effects in off-label use include:

• Transient injection site redness and warmth (most common, typically resolving within 24 hours)
• Mild fatigue increase in the first 1 to 2 weeks (possibly related to metabolic reprogramming)
• Headache in the first week at higher doses

No serious adverse events attributable to MOTS-c have been published in peer-reviewed literature as of January 2025. Given the absence of long-term human data, the theoretical risks include: off-target effects on tumor suppressor pathways (FOXO3a has dual roles in cancer biology [18]), immune over-activation in patients with underlying autoimmunity, and unknown interactions with immunosuppressive medications.

Patients on anticoagulants, biologics, or mTOR inhibitors should not use MOTS-c without explicit specialist clearance.

Regulatory and Sourcing Considerations

MOTS-c is not FDA-approved for any indication [19]. It is available as a compounded research peptide from 503A and 503B compounding pharmacies operating under USP Chapter 797 standards. The FDA's ongoing scrutiny of peptide compounding, formalized in a series of guidance documents beginning in 2023, means availability may change [19]. Patients should obtain MOTS-c only through a licensed prescribing physician working with an accredited compounding pharmacy, not through unregulated online suppliers.

The FDA's 2023 draft guidance on bulk drug substances used in compounding flagged several peptides for review. MOTS-c was not on the initial adverse-listing but is subject to the same evolving regulatory environment as BPC-157, TB-500, and similar research peptides [19].

Interpreting the Evidence: A Graded Summary

The American Society for Parenteral and Enteral Nutrition (ASPEN) evidence-grading framework, adapted for peptide therapeutics, places the current MOTS-c evidence for long-COVID at Level C (expert opinion and mechanistic rationale supported by animal and surrogate human data, without RCT confirmation) [20]. Practitioners using MOTS-c in PASC should document this clearly in patient charts and obtain written informed consent that acknowledges the off-label, pre-RCT nature of the intervention.

As the 2023 JAMA review of long-COVID therapeutics noted: "The absence of evidence is not evidence of absence, but off-label peptide use must be accompanied by rigorous outcome tracking to generate the observational data that will eventually support or refute these approaches" [1].